Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23527228 | 1.00 | MAPT (1.00) | MAPTFUCA1PDK1PDK2PDK3 | |
| SCHEMBL23564629 | 1.00 | MAPT (1.00) | MAPTFUCA1PDK1PDK2PDK3 | |
| SCHEMBL23564402 | 1.00 | MAPT (1.00) | MAPTFUCA1PDK1PDK2PDK3 | |
| SCHEMBL28498890 | 0.85 | MAPT (0.73) | MAPTFUCA1PDK1PDK2PDK3 | |
| SCHEMBL28513094 | 0.85 | MAPT (0.73) | MAPTFUCA1PDK1PDK2PDK3 | |
| SCHEMBL8936135 | 0.85 | MAPT (0.73) | MAPTFUCA1PDK1PDK2PDK3 | |
| SCHEMBL16025066 | 0.85 | MAPT (0.73) | MAPTFUCA1PDK1PDK2PDK3 | |
| SCHEMBL4130506 | 0.85 | MAPT (0.73) | MAPTFUCA1PDK1PDK2PDK3 | |
| SCHEMBL31145214 | 0.84 | MAPT (0.73) | MAPTFUCA1GBA1 | |
| SCHEMBL29324022 | 0.84 | MAPT (0.73) | MAPTFUCA1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | MAPT 4812/4885FUCA1 3024/4885PDK1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.